Trial intelligence / Profile preview

LIMIT-1 metformin after transient ischaemic attack or minor ischaemic stroke

ISRCTN54960762Phase 2Completed

Sponsor
Erasmus MC
Start
Feb 2007
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, randomised, open-label trial of metformin in prediabetes and impaired fasting glucose (IFG) (2 arms), sponsored by Erasmus MC. Primary endpoints: Tolerability of metformin treatment, Safety of metformin treatment and 1 more. Started Feb 2007; status: completed.

02

Drugs

metformin
03

Conditions

prediabetesimpaired fasting glucose (IFG)

Beyond the preview

Go deeper on ISRCTN54960762.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ISRCTN54960762.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call